Anthracycline News and Research

RSS

Anthracycline is a type of antibiotic that comes from certain types of Streptomyces bacteria. Anthracyclines are used to treat many types of cancer. Anthracyclines damage the DNA in cancer cells, causing them to die. Daunorubicin, doxorubicin, and epirubicin are anthracyclines.

Childhood cancer survivors have higher risk of developing heart disease

Survivors of childhood cancer have a higher risk of developing a range of heart disease due to cancer therapy, according to new research published in the American Heart Association's journal Circulation.

26 Aug 2019

Chemotherapy can wreak havoc on the heart

Cheryl Krafft was diagnosed with an aggressive form of non-Hodgkin's lymphoma and was put on a very high-powered chemotherapy regimen to rid her body of the cancer. What she was not counting on was the chemotherapy causing another equally deadly problem.

21 Jun 2019

CT scans used in cancer diagnostics can provide valuable clues to preventing heart problems

An imaging procedure commonly performed before starting cancer treatment can provide valuable clues about a patient's risk for heart problems in the months and years after treatment.

7 Mar 2019

Early marker of cardiac damage triggered by cancer treatment identified

Every year, 4 million new cases of cancer are diagnosed in Europe. Advances in cancer treatment sometimes come at the cost of major adverse effects, and one of the most prominent is cardiotoxicity. Myocardial toxicity affects as many as 25% of patients undergoing treatment with commonly used anticancer drugs.

19 Feb 2019

New study compares chemotherapy drugs with development of cardiomyopathy

In long-term survivors of childhood cancer, cardiovascular disease is a leading cause of early death from non-cancer causes.

1 Feb 2019

Nexus announces availability of Arsenic Trioxide Injection in the US

Nexus Pharmaceuticals announced today the immediate availability in the United States for Arsenic Trioxide Injection. Nexus Pharmaceuticals' Arsenic Trioxide Injection is available as 10 mg per 10 mL vial for injection.

16 Nov 2018

Study shows no added benefit of pertuzumab combination in treatment of early breast cancer

For the third time since 2013, the German Institute for Quality and Efficiency in Health Care (IQWiG) examined in an early benefit assessment the added benefit of the drug pertuzumab in the treatment of HER2-positive breast cancer.

12 Oct 2018

Nanoparticles show promise in treatment for triple-negative breast cancer, finds study

Approximately 10-20 percent of diagnosed breast cancers are found to be triple-negative, meaning the breast cancer cells test negative for estrogen and progesterone receptors as well as HER2 receptors, genes that can play a role in the development of breast cancer.

1 Oct 2018

FDA accepts Bristol-Myers Squibb’s application for Sprycel for treating pediatric leukemia

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration accepted its supplemental Biologics License Application for Sprycel (dasatinib) in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

30 Aug 2018

CTI BioPharma announces Phase III results of PIXUVRI combined with rituximab in aggressive B-cell NHL patients

CTI BioPharma Corp. and Servier today announced that the pivotal Phase III study evaluating PIXUVRI® combined with rituximab in comparison to gemcitabine combined with rituximab in patients with aggressive B-cell non-Hodgkin lymphoma did not meet its primary endpoint of improvement of progression-free survival

9 Jul 2018

PMDA approves use of LYNPARZA in patients with BRCA-mutated breast cancer

AstraZeneca and Merck, known as MSD outside the United States and Canada, today announced that Japan's Pharmaceuticals and Medical Devices Agency has approved LYNPARZA tablets for use in patients with unresectable or recurrent BRCA-mutated, human epidermal growth factor receptor 2 -negative breast cancer who have received prior chemotherapy.

2 Jul 2018

Combating cardiac complications caused by cancer treatment

Amie Goins has completed eight 5K runs in 2018. An impressive feat for a 46-year-old mother with a full-time job and two teenage sons to care for – downright astounding for a woman who was diagnosed with stage 2 breast cancer two days before Christmas last year. She's conquered months of treatment and difficult side effects while continuing to lace up.

26 Jun 2018

Study tests accuracy of device designed to detect heart dysfunction in childhood cancer survivors

A wireless device designed for detection of heart dysfunction in childhood cancer survivors treated with anthracycline chemotherapy was accurate and displayed a low false-negative rate as compared to cardiac magnetic resonance imaging.

21 Jun 2018

Breast cancer and lymphoma survivors at greater risk of developing heart failure

Patients who were treated for breast cancer or lymphoma are more than three times at risk for developing congestive heart failure, compared with patients who did not have cancer. Congestive heart failure is when the heart muscle does not pump blood as well as it should.

28 Feb 2018

U.S. FDA approves first drug for patients with germline BRCA-mutated metastatic breast cancer

AstraZeneca and Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved LYNPARZA (olaparib) for use in patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting.

12 Jan 2018

Men appear to have worse chemotherapy-induced cardiomyopathy than women, research shows

Men seem to have worse chemotherapy-induced cardiomyopathy than women despite receiving similar cancer treatments, according to research presented today at EuroCMR 2017.

25 May 2017

Researchers use mathematical modeling to find effective chemotherapy treatments for cancer patients

A team of Florida State University researchers is using mathematical modeling to find the best and most effective chemotherapy treatments for cancer patients.

4 May 2017

Hair loss prevention device for breast cancer patients showcased by Paxman at Vienna conference

A pioneering scalp cooling treatment that prevents alopecia in early stage breast cancer patients undergoing chemotherapy will be showcased at the 15th St. Gallen International Breast Cancer Conference, Vienna.

From Paxman 15 Mar 2017

Paxman's scalp cooling system shows to successfully reduce alopecia during chemotherapy in breast cancer patients

The results of Paxman’s first randomised US scalp cooling trial has been published in JAMA; a renowned peer-reviewed oncology medical journal published by the American Medical Association.

From Paxman 16 Feb 2017

Scalp cooling can lessen chemotherapy-induced hair loss in some breast cancer patients

Scalp cooling can lessen some chemotherapy-induced hair loss - one of the most devastating hallmarks of cancer - in certain breast cancer patients, according to a new multicenter study from UC San Francisco, Weill Cornell Medicine and three other medical centers.

15 Feb 2017